Clearstead Advisors’s Vir Biotechnology VIR Stock Holding History

Clearstead Advisors’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.2M	Sell	608,234 -608,166	-50%	-$5.79M	0.06%	220
2026 Q1	$10.9M	Buy	+1,216,400	New	+$9.69M	0.1%	160
2025 Q4	–	Sell	-373	Closed	-$2.13K	–	3269
2025 Q3	$2.13K	Buy	373 +339	+997%	+$1.73K	﹤0.01%	2430
2025 Q2	$172	Buy	+34	New	+$182	﹤0.01%	2576
2023 Q3	–	Sell	-20	Closed	-$491	–	1525
2023 Q2	$491	Hold	20	–	–	﹤0.01%	1300
2023 Q1	$466	Hold	20	–	–	﹤0.01%	1309
2022 Q4	$506	Hold	20	–	–	﹤0.01%	1231
2022 Q3	$0	Hold	20	–	–	﹤0.01%	1369
2022 Q2	$1K	Hold	20	–	–	﹤0.01%	1236
2022 Q1	$1K	Hold	20	–	–	﹤0.01%	1333
2021 Q4	$1K	Buy	20 +10	+100%	+$392	﹤0.01%	1226
2021 Q3	$0	Hold	10	–	–	﹤0.01%	1399
2021 Q2	$0	Buy	+10	New	+$455	﹤0.01%	1305

Other funds holding VIR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Clearstead Advisors's VIR Position: Q2 2026 in Review

Clearstead Advisors reduced its Vir Biotechnology (VIR) stake by 50% in Q2 2026, selling an estimated $5.79M and leaving 608,234 shares worth $6.2M. The position accounts for 0.06% of the portfolio, ranked #220.

Clearstead Advisors first reported a position in VIR in Q2 2021 and has held it in 13 quarters since. The position peaked at $10.9M in Q1 2026. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

Clearstead Advisors held 608,234 shares of Vir Biotechnology worth $6.2M as of Q2 2026.
Clearstead Advisors sold 608,166 Vir Biotechnology shares in Q2 2026, an estimated $5.79M.
Vir Biotechnology made up 0.06% of Clearstead Advisors's portfolio in Q2 2026, its #220 holding.
Clearstead Advisors first reported a position in Vir Biotechnology in Q2 2021 and has held it in 13 quarters since.
Clearstead Advisors's Vir Biotechnology position peaked at $10.9M in Q1 2026.
237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.